Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
SpringWorks Therapeutics
Biotech
Merck KGaA drops pipeline asset from SpringWorks buyout
Merck KGaA is no longer pursuing clinical-stage candidates obtained through its acquisition of SpringWorks, which centered on approved drugs.
Will Maddox
Mar 5, 2026 4:33pm
Immunome's desmoid tumor treatment triumphs in phase 3
Dec 15, 2025 10:42am
Takeda welcomes new oncology chief from CRISPR—Chutes & Ladders
Feb 9, 2024 9:30am
Immunome pays $50M for Ayala's phase 3 desmoid tumor drug
Feb 6, 2024 9:50am
SpringWorks eyes AstraZeneca's Koselugo market with phase 2 data
Nov 16, 2023 10:59am
Ayala and Advaxis fuse together to pool funds for lead programs
Oct 19, 2022 11:00am
